Compare GRRR & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRRR | PRME |
|---|---|---|
| Founded | 2001 | 2019 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.9M | 666.1M |
| IPO Year | N/A | 2022 |
| Metric | GRRR | PRME |
|---|---|---|
| Price | $11.26 | $3.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $18.00 | $6.42 |
| AVG Volume (30 Days) | 739.5K | ★ 3.8M |
| Earning Date | 11-17-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,747,682.00 | $5,977,000.00 |
| Revenue This Year | $36.15 | $111.80 |
| Revenue Next Year | $68.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 47.86 | ★ 647.13 |
| 52 Week Low | $10.85 | $1.11 |
| 52 Week High | $44.15 | $6.94 |
| Indicator | GRRR | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 34.59 | 40.00 |
| Support Level | $11.60 | $3.61 |
| Resistance Level | $12.59 | $4.12 |
| Average True Range (ATR) | 0.75 | 0.28 |
| MACD | -0.17 | -0.02 |
| Stochastic Oscillator | 0.98 | 3.14 |
Gorilla Technology Group Inc is engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.